FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2003 IGENE BIOTECHNOLOGY, INC. ______________________________________________________ (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 ____________________________ ____________ ___________________ (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 9110 Red Branch Road, Columbia, MD 21045-2024 ________________________________________ __________ (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (410) 997-2599 Item 5. Other Events Pending litigation (original lawsuit filed July 21, 1997, U.S. District Court, Baltimore, MD) between Archer Daniels Midland, Inc. ("ADM") and Igene, involving allegations of patent infringement and counterclaims concerning the theft of trade secrets was resolved on September 29, 2003. Resolution of the dispute between ADM and Igene did not result in an unfavorable outcome to Igene. Accordingly, no liability will be recorded in the balance sheet. Igene will continue to make and sell its product, AstaXin(R). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IGENE Biotechnology, Inc. _______________________________ (Registrant) By: /s/ STEPHEN F. HIU ________________________ Name: Stephen F. Hiu Title: President Dated: October 1, 2003